Birdsill Alex C, Koscik Rebecca L, Cody Karly A, Jonaitis Erin M, Cadman Robert V, Erickson Claire M, Chin Nathaniel A, Przybelski Robert J, Carlsson Cynthia M, Asthana Sanjay, Christian Bradley T, Eisenmenger Laura B, Betthauser Tobey J, Johnson Sterling C
Wisconsin Alzheimer's Disease Research Center University of Wisconsin School of Medicine and Public Health Madison Wisconsin USA.
Geriatric Research Education and Clinical Center William S. Middleton Veterans Hospital Madison Wisconsin USA.
Alzheimers Dement (Amst). 2022 Sep 20;14(1):e12360. doi: 10.1002/dad2.12360. eCollection 2022.
While it is generally appreciated that amyloid precedes symptomatic Alzheimer's disease (AD) by decades, a greater understanding of this timeline may increase prognostic accuracy, planning, and care of persons who are on the AD continuum.
We examined trajectories of Clinical Dementia Rating-Sum of Boxes (CDR-SB) relative to estimated years of amyloid positivity (A+) in = 123 participants who were all A+ based on [C-11]Pittsburgh compound B positron emission tomography.
The average amyloid chronicity at CDR-SB of 2.5 was 20.1 years. The average trajectory of CDR-SB accelerated after 10 years of elevated amyloid and varied greatly between 10 and 30 years. Exploratory analyses suggested that older age and higher volume of white matter hyperintensities shortened the interval between amyloid onset and cognitive impairment.
The recontextualization of amyloid burden into the time domain will facilitate studies of disease progression, the influence of co-pathology, and factors that hasten or slow cognitive impairment.
虽然人们普遍认识到淀粉样蛋白在出现症状的阿尔茨海默病(AD)之前数十年就已存在,但对这一时间线有更深入的了解可能会提高处于AD连续体上的人的预后准确性、规划和护理水平。
我们在123名参与者中研究了临床痴呆评定量表总和(CDR-SB)相对于估计淀粉样蛋白阳性(A+)年限的轨迹,这些参与者基于[C-11]匹兹堡化合物B正电子发射断层扫描均为A+。
CDR-SB评分为2.5时的平均淀粉样蛋白慢性病程为20.1年。淀粉样蛋白升高10年后,CDR-SB的平均轨迹加速,在10至30年之间变化很大。探索性分析表明,年龄较大和白质高信号体积较大缩短了淀粉样蛋白出现与认知障碍之间的间隔。
将淀粉样蛋白负担重新置于时域中,将有助于研究疾病进展、共病的影响以及加速或减缓认知障碍的因素。